Weekly Policy Update: CBSA Signs BIO CEO Declaration on Global Access to COVID-19 Vaccines and Treatments and the Role of Intellectual Property

Colorado BioScience Association (CBSA) and close to 300 other global biotechnology companies and associations have come together in opposition to waiving IP protections for COVID-19 vaccines and treatments. The letter outlines why life sciences organizations around the globe, including CBSA, oppose the Trade-Relations Aspects of Intellectual Property Rights (TRIPS) waiver. The waiver will harm the work to end this pandemic as well as the next one.

The signers of this declaration see it as a top priority that COVID-19 vaccines and treatments get to patients in all parts of the world, especially those who most need them. Scientists and researchers are working around the clock developing new medicines and treatments. It’s critical to continue to protect their research and innovation.

Learn more about the declaration.

CBSA strongly encourages U.S. Senators Michael Bennet and John Hickenlooper to speak out against the patent waiver for COVID-19 vaccines. CBSA made the public request in a special opinion piece published in the Colorado Sun. We emphasized that intellectual property protections are essential to the technology transfer process in life sciences that leads from lab invention to life-saving commercial product.

CBSA advocates for a supportive, pro-innovation business climate for life sciences. We support proposals to strengthen the ability of patent owners to defend their inventions and businesses against infringement.

Categories: CBSA News